NXD 3109Alternative Names: NXD-3109; Spheron targeting agents
Latest Information Update: 18 Apr 2011
At a glance
- Originator Nymox Pharmaceutical Corporation
- Class Antidementias
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 25 Aug 2004 This compound is still in active development
- 02 Oct 2001 Preclinical development for Alzheimer's disease in Canada (unspecified route)